Zanella 10mg Tablet contains dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, dapagliflozin reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels. Zanella is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It may be prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, insulin, or sulfonylureas. Clinical studies have demonstrated that dapagliflozin not only improves glycemic parameters but also contributes to weight reduction and modest blood pressure lowering, offering additional cardiovascular and renal benefits. The recommended dose is 10 mg once daily, taken orally in the morning, with or without food. Zanella should be used with caution in patients with renal impairment, and it is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored regularly for renal function and signs of volume depletion. Zanella 10mg provides an effective therapeutic option for managing hyperglycemia in type 2 diabetes mellitus.